6-diazo-5-oxo-l-norleucine Inhibition of Escherichia Coli.
نویسندگان
چکیده
Coggin, J. H., Jr. (The University of Chicago, Chicago, Ill.), and W. R. Martin. 6-Diazo-5-oxo-l-norleucine inhibition of Escherichia coli. J. Bacteriol. 89:1348-1353. 1965.-The glutamine analogue 6-diazo-5-oxo-l-norleucine (DON) induced filaments and spheroplasts in Escherichia coli during the transition of sensitive populations to a state of resistance. Resistance developed at a frequency suggesting mutant selection. The morphology of cells resistant to 100 mug of DON per ml was indistinguishable from that of sensitive cells. DON-resistant cells exhibited an extended growth lag when cultured in the absence of the drug. This extended lag could be reduced to the lag time of parent sensitive cells by a combination of d-glucosamine and inosine or by DON. Viable counts during the lag period of resistant cells indicate that this lag results from a decrease in the number of cells during the first 2 hr of incubation. A combination of d-glucosamine and inosine was required for complete prevention of the DON inhibition of sensitive cells. The results indicate that DON not only inhibits de novo purine biosynthesis but that it also prevents hexosamine synthesis and, ultimately, cell-wall synthesis in E. coli.
منابع مشابه
Effects of 6-diazo-5-oxo-L-norleucine on the incorporation of precursors into nucleic acids.
The tumor growth-inhibitor 6-diazo-5-oxo-L-norleucine (DOX) was shown to inhibit, from 90 to 98 per cent, the incorporation of formate-C14 into the purine bases of the nucleic acids from Sarcoma 180 tissue, small intestine, and liver, when given at the same time as the precursor formate. The inhibition was less, but still substantial, when the DOX was given in small multiple doses instead of a ...
متن کاملEnhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
Mouse P388 and L1210 leukemia cells grown in vitro were found to be 4 to 10 times more sensitive to 6-diazo-5-oxo-L-norleucine and 3 to 5 times more sensitive to Acivicin than were 3T3 and C57BL x DBA/2 F1 embryonic fibroblasts. The combined actions of succinylated Acinetobacter glutaminase-asparaginase and 6-diazo-5-oxo-L-norleucine or Acivicin produced synergistic inhibition of nucleic acid s...
متن کاملEnhancement of Antitumor Activity of Glutamine Antagonists 6-Diazo-5- oxo-L-norleucine and Acivicin in Cell Culture by Glutaminase- Asparaginase1
Mouse P388 and L1210 leukemia cells grown in vitro were found to be 4 to 10 times more sensitive to 6-diazo-5-oxo-Lnorleucine and 3 to 5 times more sensitive to Acivicin than were 3T3 and C57BL x DBA/2 F, embryonic fibroblasts. The combined actions of succinylated Acinetobacter glutaminaseasparaginase and 6-diazo-5-oxo-L-norleucine or Acivicin pro duced synergistic inhibition of nucleic acid sy...
متن کاملCharacterization studies on the carcinostatic activity of 5-diazouracil.
Diazouracil (2,6-dioxo-5-diazopyrimidine) (DU) is a compound which appeared worthy of study in experimental cancer chemotherapy both because of its reported action in other biological systems and because of its structural potentialities as a pyrimidine analog bearing a reactive diazo-oxo grouping similar to tha t present in azaserine and DON (6-diazo-5-oxo-L-norleucine). D U has been found to b...
متن کاملReviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
Abnormal metabolism is another cancer hallmark. The two most characterized altered metabolic pathways are high rates of glycolysis and glutaminolysis, which are natural targets for cancer therapy. Currently, a number of newer compounds to block glycolysis and glutaminolysis are being developed; nevertheless, lonidamine and 6-diazo-5-oxo-L-norleucine (DON) are two old drugs well characterized as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of bacteriology
دوره 89 شماره
صفحات -
تاریخ انتشار 1965